Headache News and Research RSS Feed - Headache News and Research

In medicine a headache or cephalalgia is a symptom of a number of different conditions of the head. Some of the causes are benign while others are medical emergencies.
Further Reading
Migranade makes available new migraine medication for U.S. migraine sufferers

Migranade makes available new migraine medication for U.S. migraine sufferers

Migranade, Inc. announced today the new migraine medication, MIGRANADE Migraine Relief will be available to the 36 million U.S. migraine sufferers November, 2014. [More]
Avanir Pharmaceuticals to publish AVP-825 phase III study results in the journal 'Headache'

Avanir Pharmaceuticals to publish AVP-825 phase III study results in the journal 'Headache'

Avanir Pharmaceuticals, Inc. today announced the publication of results from TARGET, a pivotal phase III study evaluating the efficacy and safety of AVP-825 22mg in the January 2015 issue of Headache (Early access is now available). [More]
Working under hot sun causes health problems for sugarcane harvesters

Working under hot sun causes health problems for sugarcane harvesters

Hard work under hot sun causes health problems for sugar cane workers in Costa Rica, such as headache, nausea, and renal dysfunction. The presence of symptoms is also expected to increase in line with ongoing climate changes, according to a dissertation from Umeå University. [More]

electroCore’s gammaCore device effective for treating migraines, shows trial results

Preliminary results of an open-label trial carried in the journal of Headache and Pain reported that a single treatment with electroCore’s hand held non-invasive vagus nerve stimulation (nVNS) device gammaCore, completely resolved 44.8% of migraines within 30 minutes, with an additional 11.4% experiencing moderate benefits (incomplete resolution of their headaches) by 2 hours. [More]
Passengers from West Africa to start 3-week Ebola screening

Passengers from West Africa to start 3-week Ebola screening

The Centers for Disease Control and Prevention has announced that any person flying into the USA from Liberia, Sierra Leone or Guinea will soon have to undergo daily Ebola monitoring for several weeks after their arrival. [More]
CHLA pediatric specialist discusses how parents can help children prevent Ebola outbreak

CHLA pediatric specialist discusses how parents can help children prevent Ebola outbreak

For many months, the world has witnessed the Ebola virus spread and claim more than 4,400 lives in West African countries. On Oct. 8, the first confirmed adult Ebola patient identified in the United States died. The constant news coverage has heightened concern among parents who fear their children will become infected. Jill Hoffman, MD, a pediatric Infectious diseases specialist at Children's Hospital Los Angeles, discusses the facts about Ebola, how parents can help their children prevent further outbreak by teaching them good hygiene, and how CHLA is prepared to identify and treat suspected Ebola patients. [More]
Myths, misconceptions about seasonal flu and flu vaccine

Myths, misconceptions about seasonal flu and flu vaccine

It's that time of year again. As days shorten, evenings become chilly and the trees start a showy display of color, it's time to roll up your sleeve and get your annual flu vaccine. [More]
Epidural and spinal anesthesia safe for relieving pain during childbirth

Epidural and spinal anesthesia safe for relieving pain during childbirth

Women seeking pain relief during childbirth should be comforted to know that epidural and spinal anesthesia are extremely safe, suggests a study of more than 80,000 women that reviewed anesthesia complications during obstetrical care. [More]
Boehringer Ingelheim's OFEV (nintedanib) capsules receive FDA approval for IPF treatment

Boehringer Ingelheim's OFEV (nintedanib) capsules receive FDA approval for IPF treatment

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration approved OFEV (nintedanib) capsules for oral use for the treatment of idiopathic pulmonary fibrosis (IPF). [More]
Loyola neurologist lists seven surprising things about strokes

Loyola neurologist lists seven surprising things about strokes

In recognition of World Stroke Day Oct. 29, Loyola University Medical Center neurologist Jose Biller, MD, lists seven surprising things you may not know about strokes. [More]
Eisai, Helsinn Group announce FDA approval of AKYNZEO for prevention of CINV

Eisai, Helsinn Group announce FDA approval of AKYNZEO for prevention of CINV

Helsinn Group and Eisai Inc. announced today that the Food and Drug Administration (FDA) approved AKYNZEO® for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. [More]
Views on giving flu shot to younger children

Views on giving flu shot to younger children

It's a common question parents ask themselves this time of year: Does my child really need a flu shot? Though the flu may seem harmless, the truth is on average 20,000 children age 5 and younger are hospitalized due to flu symptoms each year. [More]
Kansas State professor aims to develop vaccines to protect against tick-borne diseases

Kansas State professor aims to develop vaccines to protect against tick-borne diseases

A Kansas State University professor is researching ways to keep animals and humans safe from tick-borne diseases. [More]
Ferring Pharmaceuticals to introduce new cranberry flavor option of PREPOPIK in 2015

Ferring Pharmaceuticals to introduce new cranberry flavor option of PREPOPIK in 2015

Colonoscopy is an important and widely used screening tool for colorectal cancer, but for many patients the bowel-preparation process is more uncomfortable than the procedure itself. To offer an alternative choice in bowel preparation, Ferring Pharmaceuticals Inc. will introduce a new cranberry flavor option of PREPOPIK in January 2015. [More]
Care lags for people who have stroke in hospital, study finds

Care lags for people who have stroke in hospital, study finds

At the first sign of a stroke, time is of the essence. For every minute of delay in treatment, people typically lose almost two million brain cells. Yet a new study presented at the Canadian Stroke Congress reveals that those delays - in getting the right tests and the right drugs - can be longer when people experience a stroke in a hospital. [More]
Researchers reveal that drug-food interactions may endanger mountaineer’s health

Researchers reveal that drug-food interactions may endanger mountaineer’s health

University of the Basque Country researchers have studied the nutritional and health situations existing at high altitudes as well as the routinely used nutritional ergogenic and pharmacological aids. According to their study, the possible interactions between drugs and food and nutrients taken may endanger the mountaineer’s health if all this is not conducted under strict control. [More]
Family physician  answers questions related to Ebola virus

Family physician answers questions related to Ebola virus

According to the Centers for Disease Control, the outbreak of Ebola in four West African countries is one of the largest outbreaks of the disease in history. [More]
Today is the deadline for thousands to provide information to keep subsidies

Today is the deadline for thousands to provide information to keep subsidies

The administration has notified more than 300,000 people that they need to provide documentation to keep their health insurance subsidies. [More]
Sanofi, Regeneron report positive Phase 2 study of dupilumab in patients with CSwNP

Sanofi, Regeneron report positive Phase 2 study of dupilumab in patients with CSwNP

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced that a Phase 2a proof-of-concept study of dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, met all primary and secondary endpoints in patients with moderate-to-severe chronic sinusitis with nasal polyps (CSwNP) who did not respond to intranasal corticosteroids. [More]
GSK reports 45% survival rate in phase III study of Tafinlar in BRAF V600E mutant metastatic melanoma

GSK reports 45% survival rate in phase III study of Tafinlar in BRAF V600E mutant metastatic melanoma

GSK today announced updated results for Tafinlar (dabrafenib) from a planned analysis of the phase III BREAK-3 study in 250 patients with BRAF V600E mutant metastatic melanoma. [More]